Global Care Capital

Global Care Capital focuses on early-stage investments, typically participating in seed and Series A rounds. The firm engages with companies that are often pre-revenue or in early clinical validation, aiming to provide the first institutional capital that enables regulatory submissions and initial commercialization. It has shown a preference for acting as a lead investor to secure board seats and influence strategic direction during the formative stages of a company's lifecycle.

The firm maintains a strict focus on healthcare, life sciences, and adjacent AI/ML applications. It does not pursue opportunities in consumer internet, enterprise SaaS outside of health, fintech, or industrial technologies. This deliberate concentration means the firm will pass on otherwise attractive deals that fall outside its clinical and regulatory competence.

The firm sources investment opportunities primarily through academic medical centers, clinical research networks, and relationships with venture studios specializing in life sciences. Unlike generalist funds that rely heavily on inbound pitch decks or investment bank introductions, Global Care Capital cultivates a network of practicing clinicians and translational researchers who surface technologies before formal fundraising processes commence. This origination model is designed to provide access to scientifically vetted opportunities at valuation points that precede broader market awareness.

The firm operates as a direct investor in operating companies rather than as a fund-of-funds allocating to other managers. Its activity is concentrated in equity financings of private healthcare companies, and there is no public record of the firm making limited partner commitments to third-party venture capital or private equity funds.

While headquartered in Vancouver, the firm pursues opportunities across North America, Europe, and select Asia-Pacific markets. It does not restrict deployment by region, preferring to follow specific subsector theses — such as digital therapeutics or AI-enabled diagnostics — wherever the strongest scientific teams and regulatory pathways exist. Australia, the United Kingdom, and Israel have been particular areas of observable activity alongside North American investments.